top of page
Search

Retatrutide Phase 3 Results: Knee Pain, Inflammation, and the Skin Sensation Side Effect Nobody Is Talking About

  • Writer: Rob Lagana
    Rob Lagana
  • Apr 8
  • 5 min read
Retatrutide Phase 3 TRIUMPH-4 trial results — knee inflammation reduction and dysesthesia side effect data visualization

The first Phase 3 data for Retatrutide dropped on December 11, 2025. The headlines covered the 28.7% weight loss figure — which is legitimately extraordinary. But two other findings from the TRIUMPH-4 trial deserve serious attention, and most of the coverage either missed them entirely or got them wrong.


The first is Retatrutide's effect on joint pain and systemic inflammation. The second is a newly confirmed side effect called dysesthesia — abnormal skin sensations — that is generating confusion and, in some cases, unnecessary alarm among people currently on the compound.


Both findings are clinically significant. Both have direct implications for how Retatrutide should be used. And both reinforce the same core argument that PowerSkulpt has been making since we started working with this compound: the dose you choose matters more than most prescribers are telling you.


What the Retatrutide Phase 3 Trial Actually Found on Knee Pain and Inflammation


TRIUMPH-4 (NCT05931367) was a 68-week, Phase 3, randomized, double-blind, placebo-controlled study. It enrolled 445 adults with obesity or overweight and knee osteoarthritis — a population that directly overlaps with the adults over 40 that PowerSkulpt works with.

The pain outcomes were measured using the WOMAC pain subscale, which is the clinical standard for osteoarthritis research. The results were not subtle.


Participants on the 9 mg dose saw an average 4.5-point reduction on the WOMAC pain scale. Participants on the 12 mg dose saw a 4.4-point reduction. The placebo group improved by 2.4 points — the expected background improvement from being in a supervised study. On a percentage basis, the retatrutide groups achieved approximately 75–76% reduction in knee pain scores.


More than one in eight patients on retatrutide reported being completely free of knee pain at week 68, compared to 4.2% in the placebo group.


The trial also reported clinically meaningful improvements in cardiovascular risk factors, including a reduction in high-sensitivity C-reactive protein (hsCRP) — which is a direct marker of systemic inflammation, not just mechanical joint load.


That last point is important. Some of the knee pain improvement is attributable to weight loss reducing mechanical load on the joint. That's straightforward physics. But the hsCRP reduction tells a different story: Retatrutide is also doing something anti-inflammatory at a systemic level. The glucagon receptor component of the compound — the third receptor that distinguishes it from semaglutide and tirzepatide — likely plays a role here, though the precise mechanism is still being studied.


For adults over 40 dealing with chronic joint pain, low-grade systemic inflammation, or inflammatory markers that have crept up over time, this is not a minor secondary finding. It suggests that Retatrutide's benefits extend significantly beyond the scale number.


Retatrutide Phase 3 Results and the Recovery-First Framework


At PowerSkulpt, we've been describing Retatrutide's potential for systemic benefit for some time. The Phase 3 data now gives that argument clinical weight.


The adults who respond best to this compound are not simply people who want to lose weight. They are people whose physiology has accumulated years of compounding stress — elevated cortisol, insulin resistance, poor sleep, chronic low-grade inflammation, declining hormonal output. The weight on the scale is often the most visible symptom of a broader metabolic problem.


When a compound simultaneously reduces fat mass, improves insulin sensitivity, lowers systemic inflammation, and reduces joint pain, it is addressing multiple nodes of that problem at once. That's not marketing language. That's what the Phase 3 data now supports.


What Is Dysesthesia, and Why Is It Appearing in Retatrutide Users?


Dysesthesia is an abnormal sensation affecting how the skin perceives touch. It can manifest as tingling, burning, pins-and-needles, unusual sensitivity, or a sensation of skin feeling wet or electric when nothing is touching it. It's not a pleasant experience, and for people who don't know what it is, it can be alarming.


Dysesthesia was identified as a new safety signal in the TRIUMPH-4 Phase 3 data. It affected 20.9% of participants at the 12 mg dose and 8.8% at the 9 mg dose, compared to 0.7% in the placebo group. It had not been prominently documented in the Phase 2 trial — the larger Phase 3 sample size and longer 68-week duration allowed the signal to become visible.


The mechanism is not yet fully established. The leading hypotheses involve GLP-1 receptor activity on peripheral nerves — altering how sensory signals are transmitted — and Retatrutide's glucagon receptor agonism, which neither semaglutide nor tirzepatide possess. Glucagon receptors are expressed in nervous system tissue, and the additional receptor activation may amplify a neurological effect that exists at lower levels in the broader GLP-1 drug class.


The dose-dependency is the critical piece of information. In the Type 2 diabetes Phase 3 trial (TRANSCEND-T2D-1), which used lower target doses, dysesthesia occurred in only 2.3–4.5% of participants — a fraction of the rate seen at 12 mg. The pattern is consistent across multiple trials: more receptor activation at higher doses means a higher probability of this side effect appearing.


Why the Retatrutide Phase 3 Data on Dysesthesia Validates Conservative Dosing


The clinical trial doses tested in TRIUMPH-4 — 9 mg and 12 mg weekly — are not representative of how informed practitioners use this compound outside of the high-dose research context.


At PowerSkulpt, our protocols operate at a fraction of those doses. The rationale has always been clinical: the dose-response curve for fat loss flattens significantly as dose increases, while the dose-response curve for side effects continues to climb. You reach a point where adding more compound adds meaningfully more side effect risk without adding meaningfully more benefit.


The TRIUMPH-4 dysesthesia data makes this argument in hard numbers. Moving from 9 mg to 12 mg per week increases dysesthesia incidence from 8.8% to 20.9% — more than doubling the risk — while adding a modest increment to weight loss outcomes that most users would not distinguish from normal variation.


This is not a cautious or conservative position. It is the position supported by the data.

The 12 mg dose exists because Eli Lilly needed to test dose-ceiling efficacy in a registration trial. That does not mean 12 mg is the optimal clinical dose for the population that will actually use this compound. In practice, the adults who benefit most from Retatrutide — people over 40 with insulin resistance, metabolic dysfunction, and years of accumulated physiological stress — are often more sensitive to the compound's effects, not less. A lower dose, titrated deliberately, with full attention to recovery variables, typically produces better outcomes in this population than aggressive escalation.


The Phase 3 data reinforces what precision dosing already suggested: chasing the highest dose available is a marketing approach, not a clinical one.


Training creates the signal. Recovery creates the change.


Most programs start with training. PowerSkulpt starts with recovery.


Not sure how your current Retatrutide protocol is performing? Use the Retatrutide Troubleshooter — a free interactive diagnostic tool that identifies the specific variables stalling your results, including side effects like dysesthesia:



If you're experiencing dysesthesia or have questions about your current dose, book a consultation with Rob and Robin Lagana:



Related reading:


bottom of page